Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence-Reference-Cited by-同舟云学术

Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence

Published:2022-08 Issue:4 Volume:46 Page:100875
ISSN:0147-0272
Container-title:Current Problems in Cancer
language:en
Short-container-title:Current Problems in Cancer

Author:

Capitanio Umberto,Fallara Giuseppe,Raggi Daniele,Nocera Luigi,Larcher Alessandro,Belladelli Federico^ORCID,Rowe Isaline,Briganti Alberto,Salonia Andrea,Karakiewicz Pierre,Montorsi Francesco,Martini Alberto,Necchi Andrea

Funder

Clovis Oncology

Merck

Ipsen

Roche

AstraZeneca

Bayer

Janssen Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;New Engl J Med,2007

2. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial;Motzer;Lancet Oncol,2019

3. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial;Albiges;Esmo Open,2020

4. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;New Engl J Med,2019

5. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights;OncoTargets and Therapy;2023-09

2. Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy;World Journal of Urology;2023-05-06